Measles Virus as an Oncolytic Immunotherapy

Simple Summary Measles virus is currently under investigation as an innovative cancer treatment. The virus selectively replicates in and kills cancer cells. Furthermore, it can be genetically engineered to increase tumor specificity and therapeutic efficacy. Importantly, treatment with measles virus activates antitumor immune responses. A number of clinical trials using measles virus for cancer treatment have been completed or are ongoing. Future studies will further harness the possibilities of virus engineering and potential of combination immunotherapies to improve clinical outcome. Measles virus (MeV) preferentially replicates in malignant cells, leading to tumor lysis and priming of antitumor immunity. Live attenuated MeV vaccine strains are therefore under investigation as cancer therapeutics. The versatile MeV reverse genetics systems allows for engineering of advanced targeted, armed, and shielded oncolytic viral vectors. Therapeutic efficacy can further be enhanced by combination treatments. An emerging focus in this regard is combination immunotherapy, especially with immune checkpoint blockade. Despite challenges arising from antiviral immunity, availability of preclinical models, and GMP production, early clinical trials have demonstrated safety of oncolytic MeV and yielded promising efficacy data. Future clinical trials with engineered viruses, rational combination regimens, and comprehensive translational research programs will realize the potential of oncolytic immunotherapy.